1.	Biological, Pathological and Imagery Markers in the First-Line Treatment of Metastatic Clear-Cell Renal Cell Carcinoma Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: P070104, NCT00930345
2.	Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients Phase: Phase IV Type: Natural history/Epidemiology Status: Active Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: A6181118, NCT01073644
3.	Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: SG 327/10, NCT01402089
4.	A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A6181202, NCT01525550
5.	Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000681319, FFCD-PRODIGE-16, FFCD-0905, EUDRACT-2009-017064-16, EU-21050, FFCD 0905-PRODIGE 16, NCT01164202
6.	SU011248 versus Interferon-alfa as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A6181034, UCLA-0406015-01, PFIZER-A6181034, NCT00083889
7.	A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A6181109, NCT00375674
8.	Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00469, CALGB 30607, CDR0000597649, U10CA031946, NCT00693992
9.	Exercise for Patients With Renal Cell Cancer Receiving Sunitinib Phase: Phase III Type: Supportive care Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: SUIR8687, NCT00869011
10.	Clinical Trial to Assess the Importance of Nephrectomy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: P070144, NCT00930033
11.	Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: EORTC-30073, EU-21022, PFIZER-EORTC-30073, NCT01099423
12.	Caphosol in Oral Mucositis Due to Targeted Therapy Phase: Phase III Type: Supportive care Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: Esperanz-002, NCT01265810
13.	Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST) Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CSTI571BDE78T, NCT01462994
14.	Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AGS-003-007, 2012-000871-17, NCT01582672
15.	A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AB11002, NCT01694277
16.	Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GCO 06-0906, NCT00463060
17.	Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: ASSG01, NCT00753727
18.	Phase I/II Randomized Pilot Study of Neoadjuvant Therapy Comprising Sunitinib Malate and Exemestane in Postmenopausal Women With Hormone Receptor-Positive and HER-2 Negative Primary Breast Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Postmenopausal Sponsor: Other Protocol IDs: ICO-SUT-EXE-08, SUT-EXE-08, PFIZER-ICO-SUT-EXE-08, NCT00931450
19.	A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 6 to 21 Sponsor: Pharmaceutical / Industry Protocol IDs: A6181196, NCT01396148
20.	Phase II Pilot Study of Adjuvant Sunitinib Malate, Tamoxifen Citrate, and Cisplatin in Patients With High-Risk Ocular Melanoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: POHA-0604, 06-04, NCT00489944
21.	A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 to 90 Sponsor: Other Protocol IDs: 07-0017-C, NCT00480935
22.	Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000569863, FRE-FNCLCC-GEP-03-0603, EU-20761, EUDRACT-2006-003339-62, PFIZER-FRE-FNCLCC-GEP-03-0603, FNCLCC-GEP 03/0603, NCT00541008
23.	Phase II Study of Sunitinib Malate in Patients With Recurrent or Unresectable Meningioma, Intracranial Hemangiopericytoma, or Intracranial Hemangioblastoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MSKCC-07135, 07-135, PFIZER-MSKCC-07135, NCT00561665
24.	Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 07-212, NCT00556049
25.	Brain Mets - Capecitabine and WBRT Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: H-20924, Brain Mets Radiation Study, NCT00570908